Stock exchanges & markets

Overview Watchlists

FDA accepts Roche unit Genentech vamikibart filing for uveitic macular edema treatment

10. Oct 2026

(AWP Alliance News) - Roche unit Genentech won FDA acceptance of its biologics license application for vamikibart to treat uveitic macular edema. The agency set a decision deadline for July 2027. Genentech also filed applications that have been accepted in the EU, China, and Japan.

https://www.businesswire.com/news/home/20261010064674/en/

Disclaimer: This news brief was created using generative artificial intelligence. Roche Holding AG published the original content used to generate this news brief via Business Wire on October 10, 2026, and is solely responsible for the information contained therein.

Learn more about our offers

  • Keep a close eye on your favourite shares

    Watchlist

    Don’t miss out on share price trends. Track your favourite shares (CH, EU & US) in real time with customised watchlists.

    Sign up now

  • Compare ETFs systematically

    ETF Compass

    Find the products that suit your investment goals.

    Try the ETF Compass

  • How to find the best shares

    theScreener

    Search through around 6,500 securities using criteria such as opportunities and risks or expected dividend yield.

    Test now